NEW

DRUG

CONCEPTS

DEVELOPING A HEALTHIER FUTURE

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

James Yarger, Ph.D.

CEO

LATEST NEWS

ENDECE is preparing to take NDC-1308 into clinical studies. Our Dual Mechanism of Action (MOA) allows NDC-1308 to provide an anti-inflammatory environment and directly induce remyelination within the Central Nervous System (CNS). This dual MOA allows ENDECE to treat diseases such as Niemann-Pick disease type C, Neuromyelitis Optica Spectrum Disorder (NMOSD), Multiple Sclerosis (MS), and Alzheimer’s Disease.

NDC-1308  –  A DUAL MECHANISM OF ACTION

ANTI-INFLAMMATORY

NDC-1308 directly up-regulates the Lipoprotein Lipase (LPL) gene and functional protein expression, polarizing macrophages to the pro-repair, anti-inflammatory M2-like state.

REMYELINATION

NDC-1308 directly up-regulates key genes within Oligodendrocyte Progenitor Cells (OPCs) of the Central Nervous System (CNS), inducing OPC differentiation to mature, myelinating Oligodendrocytes.